Sun Pharmaceutical Industries Ltd.

SUNPHARMA

INE044A01036

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 12:43:55 14/06/2024 BST			5-day change	1st Jan Change
1,516 ^INR	+0.34%		+0.61%	+20.37%

06-07	Sun Pharmaceutical to Acquire 9.6% Stake in Genome Software Haystack Analytics	MT
06-06	Sun Pharmaceutical Industries Limited agreed to acquire 9.61% stake in HaystackAnalytics Pvt. Ltd. for INR 330 million.	CI

Sun Pharmaceutical Industries Limited Appoints Dilip Shanghvi as Chairman of Board

May 22, 2024 at 10:35 am

Sun Pharmaceutical Industries Limited at its board meeting held on May 22, 2024, appointed Mr. Dilip Shanghvi, Managing Director of the Company as the Chairman of the Board with immediate effect.

Latest news about Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical to Acquire 9.6% Stake in Genome Software Haystack Analytics	06-07	MT
Sun Pharmaceutical Industries Limited agreed to acquire 9.61% stake in HaystackAnalytics Pvt. Ltd. for INR 330 million.	06-05	CI
Sun Pharmaceutical Industries Limited Receives an Order Passed by Joint Commissioner of State Tax CT& GST -Territorial Range -Bhubaneswar	06-04	CI
Philogen, Inc. and Sun Pharmaceutical Industries Limited Announces Results of the Phase III PIVOTAL Trial of Nidlegy in Melanoma	05-31	CI
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research	05-27	RE
Sun Pharma to Pursue M&A	05-24	CI
Taro Pharmaceutical's Shareholders Approve Merger With Sun Pharmaceutical	05-23	MT
Indian Equities Hit Intraday Record Highs on Thursday, Lifted by Easing Poll Worries, Strong Domestic Buying	05-23	MT
Sun Pharmaceutical Clocks Gains in Fiscal Q4 Consolidated Net Profit	05-23	MT
Transcript : Sun Pharmaceutical Industries Limited, Q4 2024 Earnings Call, May 22, 2024	05-22
Sun Pharmaceutical Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-22	CI
India's Sun Pharma beats Q4 profit estimates	05-22	RE
Sun Pharmaceutical Industries Limited Recommends Final Dividend for the Financial Year 2023-2024	05-22	CI
Sun Pharmaceutical Industries Limited Appoints Dilip Shanghvi as Chairman of Board	05-22	CI
India's Alembic Pharma posts higher Q4 profit on strong N.America sales	05-09	RE
Sun Pharmaceutical Industries Limited Receives an Order Passed by Joint Commissioner Secunderabad, Telangana	05-08	CI
Sun Pharmaceutical Industries Limited entered into an agreement to acquire Valstar Investment S.a. for an enterprise value of $31 million.	05-03	CI
Sun Pharmaceutical Industries Limited Receives an Order Passed by Deputy Commissioner, DGSTO-5, Bengaluru, Karnataka	04-30	CI
Sun Pharmaceutical Industries Limited Company Receives an Order Passed by Jt. Commissioner, CGST and Central Excise	04-29	CI
Indian Equities End Higher for Third Straight Day, Lifted by Real Estate, IT Stocks	04-23	MT
Sun Pharmaceutical Industries Limited Company Receives an Order Passed by Asst. Commissioner (S.T) Madurantagam Assessment Circle	04-19	CI
Sun Pharmaceutical Industries Limited Company Receives an Order Passed by Deputy Commissioner of State Tax, Ropar, Punjab	04-17	CI
Indian Equities Close Lower on Friday As Hopes for US Rate Cute in June Fade	04-12	MT
Sun Pharmaceutical's Dadra, India Unit Gets 'Official Action Indicated' Status from US FDA	04-12	MT
INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes	04-12	RE

Chart Sun Pharmaceutical Industries Ltd.

Duration

Period

Chart Sun Pharmaceutical Industries Ltd.

More charts

Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows: - generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment; - other (6%) : primarily active pharmaceutical ingredients. At the end of March 2021, the group had 44 production plants worldwide. Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).

Sector

Pharmaceuticals

Calendar

17/06/2024 - Nuvama Speciality Chemicals & Healthcare Day

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Sun Pharmaceutical Industries Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,516 INR

Average target price

1,619 INR

Spread / Average Target

+6.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.37%	43.54B
OTSUKA HOLDINGS CO., LTD.	+17.66%	21.78B
SANDOZ GROUP AG	+17.85%	15.38B
CIPLA LIMITED	+25.55%	15.12B
ZYDUS LIFESCIENCES LIMITED	+60.99%	13.36B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-15.32%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.17%	5.32B
KRKA, D. D.	+26.36%	4.58B

Generic Pharmaceuticals

Sun Pharmaceutical Industries Ltd.

Equities

SUNPHARMA

INE044A01036

Pharmaceuticals

Sun Pharmaceutical Industries Limited Appoints Dilip Shanghvi as Chairman of Board

EPS Revisions